The anandamide membrane transporter and the therapeutic implications of its inhibition
| Autor: | Natalia Battista, Filomena Fezza, Valeria Gasperi, Mauro Maccarrone |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Cannabinoid receptor
AM404 Biology Neurodegenerative disease Arvanil chemistry.chemical_compound VDM13 Fatty acid amide hydrolase Olvanil Pharmacology (medical) Settore BIO/10 Cannabinoid receptors VDM11 UCM707 Vanilloid receptor chemistry.chemical_classification Membrane transport AM1172 OMDM2 Anandamide OMDM1 General Medicine Lipid signaling Endocannabinoid system chemistry Biochemistry O-2109 lipids (amino acids peptides and proteins) Therapy Polyunsaturated fatty acid |
| Zdroj: | Therapy. 2:141-150 |
| ISSN: | 1744-831X 1475-0708 |
| DOI: | 10.1586/14750708.2.1.141 |
| Popis: | Endocannabinoids are a new class of lipid mediators that include amides, esters and ethers of long chain polyunsaturated fatty acids. Anandamide (N-arachidonoylethanolamine), the most prominent member of this group together with 2-arachidonoyl glycerol, has several pharmacological actions, even if its life span is quite short because of the presence of an efficient mechanism of cellular removal which involves transport across the plasma membranes and hydrolysis by fatty acid amide hydrolase (FAAH). Here, we review evidence in favor or against the existence of a true anandamide membrane transporter (AMT) and discuss the structural properties of compounds that inhibit AMT without affecting other proteins of the endocannabinoid system, such as cannabinoid receptors or FAAH. Also the therapeutic implications of novel AMT inhibitors will be reviewed in the light of their potential exploitation for the treatment of neurodegenerative diseases and other human pathologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|